Novo Nordisk and Hims & Hers have ended a legal feud with an agreement that allows the telehealth platform to sell the pharma giant’s blockbuster brand-name GLP-1 drugs. In separate statements issued ...

Hims & Hers (HIMS) stock fell 39% in 2026 after shifting to branded GLP-1 drugs. Amazon's Foundayo launch adds pressure.

Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk’s branded weight loss ...

Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see branded semaglutide (Ozempic, Wegovy) ...

Novo Nordisk is dismissing its patent infringement lawsuit against telehealth company Hims & Hers, as the two companies have reached an agreement that will see Novo Nordisk's branded weight loss ...

The CEO said Hims shipped its first Novo Nordisk medicines nearly two weeks ago. ・As part of the Novo deal, patients gained access to multiple Wegovy injection and pill dose options. ・Dudum’s outlook ...

Novo Nordisk (NVO) stock is in focus as the company launches a Wegovy subscription program via telehealth firms including ...

Hims & Hers Health (HIMS) said that it has begun selling Novo Nordisk (NVO) GLP-1 medicines Wegovy (semaglutide) and Ozempic (semaglutide), which are indicated for weight loss and type 2 diabetes. All ...

To say that pharmaceutical giant Novo Nordisk (NYSE: NVO) has had a tumultuous relationship with telehealth company Hims & Hers Health (NYSE: HIMS) in the past year would be a bit of an understatement ...

Novo Nordisk is dropping its lawsuit against Hims & Hers Health, as it has reached an agreement with the telehealth company. The deal will permit Hims & Hers Health to sell Ozempic and Wegovy on its ...